BioFire® Respiratory 2.1-EZ (RP2.1-EZ) Panel (EUA)* by Biofire Diagnostics

Manufacturer Biofire Diagnostics  |  Available in North America, South Central America
The Emergency Use Authorized BioFire® Respiratory 2.1-EZ (RP2.1-EZ) Panel (EUA)* uses a molecular syndromic approach to accurately detect and identify a wide range of pathogens—not just SARS-CoV-2 or influenza—providing an accurate, comprehensive alternative to targeted testing. 1 test. 19 pathogens. Results in about 1 hour. *This test has not been FDA cleared or approved. This test has been authorized by the FDA under an EUA for use by authorized laboratories. See product Descr


BioFire® Respiratory 2.1-EZ (RP2.1-EZ) Panel (EUA)* by Biofire Diagnostics product image
BioFire® Respiratory 2.1-EZ (RP2.1-EZ) Panel (EUA)*
Request Pricing

Receive your quote directly from the manufacturer.



0 Scientists have reviewed this product


Write the First Review

No Reviews

The BioFire® Respiratory 2.1-EZ (RP2.1-EZ) Panel (EUA)* detects and identifies a comprehensive menu of respiratory pathogens, including 15 viruses and 4 bacteria, providing an alternative to targeted SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) testing. This helps to ensure that your patients can receive the right treatment, the first time, potentially leading to higher patient satisfaction and lower costs. And as the name implies, it’s easy and can be performed right in your office with a CLIA Certificate of Waiver.

  • Detects and identifies 19 respiratory pathogens, including SARS-CoV-2.
  • Results are available in about 1 hour.
  • Designed to run on a single computer/instrument configuration (EZ Configuration) of the BioFire® FilmArray® 2.0 System.

*This test has not been FDA cleared or approved; this test has been authorized by FDA under an EUA for use by authorized laboratories; this test has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.